Chimerix Raises $11 Million in Series C Financing to Advance Smallpox Drug and Other Antiviral Therapeutics
SAN DIEGO -- Chimerix Inc., a biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the round, and Robert Overell, Ph.D., a general partner with Frazier Healthcare Ventures, will join Chimerix's board of directors. Additional funding for the round came from founding investors Sanderling Ventures and Asset Management Company.
"This financing provides resources for the company to advance our current therapeutic programs and to broaden the application of our proprietary technology to new commercially attractive therapeutic indications," said George Painter, PhD, president and CEO of Chimerix, Inc. "The funds will allow Chimerix to acquire additional developmental resources as we advance CMX001, our lead antiviral agent for treatment of smallpox infection, toward clinical trials. I would like to welcome Bob to Chimerix's board of directors and to thank our founding and existing investors, Sanderling Ventures and Asset Management Company for their continued confidence in the company's progress, technology and therapeutic pipeline."
The financing will augment a $36.1 million grant from the National Institutes of Health awarded to Chimerix for the development of CMX001 for the prophylaxis and treatment of smallpox infection and will allow Chimerix to accelerate development programs for treating cytomegalovirus infection, multi-drug resistant HIV-1 infection, viral hepatitis and other discovery-stage preclinical programs.
"Chimerix has a proven platform that corrects undesirable absorption, distribution, metabolism and elimination (ADME) properties of drug candidates for viral diseases," said Robert Overell, PhD "Chimerix's technology addresses this critical problem in drug development and has led to the successful creation of a therapeutic portfolio of preclinical compounds to treat a variety of human diseases, including smallpox."
Source: Chimerix Inc.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
